Baylor College Of Medicine

Baylor College of Medicine, a private nonprofit research-intensive academic health sciences institution headquartered in Houston, Texas, operates as a federal grant recipient and contract prime across biomedical research, clinical services, and specialized medical laboratory work—delivering services worth $3.77 billion across a portfolio of 4,979 prime and sub awards spanning 62 years of federal engagement. The institution competes full-and-open across NIH programs (no set-asides) and serves 136 distinct federal customer agencies, with recompete exposure of $257.1 million across 409 awards maturing in the next twenty-four months.

Baylor's capability portfolio centers on federally funded biomedical research spanning precision medicine genomics, oncology, immunology, cardiovascular disease, infectious disease, and translational science, alongside delivery of clinical transplant laboratory testing, expert witness services, and specialized medical services to the Veterans Health Administration. Recent contract work exemplifies this scope: a $11.3 million firm-fixed-price delivery order from the National Heart Lung and Blood Institute (September 2026) for Trans-Omics for Precision Medicine (TOPMED) Centralized Omics Resource infrastructure and services supporting genomic sequencing and clinical laboratory work; $2.6 million from Veterans Integrated Service Network 17 for on-site liver and kidney transplant services at Houston VA (April 2026, Option Year 2); $2.0 million from VISN 17 for heart transplant and VAD services (February 2026); and $2.0 million from VISN 17 for transplant laboratory testing services (August 2026). On the grant side, Baylor holds a substantial portfolio anchored by NIH project grants in cancer biology ($602 thousand, NCI, selenoprotein biosynthesis in AML; $663 thousand, NCI, liquid biomarkers in mesothelioma), cardiovascular disease ($1.6 billion, NHLBI, across alveolar remodeling, mitochondrial calcium exchange, hepatic dysfunction and arrhythmogenesis, and clonal hematopoiesis studies), immunology ($2.4 million, NIAID, microbiome-based antibiotic resistance strategies across mucosal surfaces), and aging research ($651 thousand, NIA, periosteal skeletal stem cells in bone maintenance; $689 thousand, NIA, hepatic epigenetic memory and metabolic resilience).

Customer concentration is pronounced within NIH and the Veterans Health Administration. The top five funding entities account for 45% of awards by count: NIH broadly (938 awards); NCI (482 awards, $108.7 million combined potential value); NHLBI (298 awards, $1.29 billion combined potential value); NIAID (274 awards, $1.2 billion combined potential value); and NIDDK (236 awards, $74 thousand combined potential value). By dollar value, NHLBI and NIAID dominate, representing $2.49 billion of the $3.77 billion combined potential value—73% concentration. VISN 17 (Veterans Health Administration) anchors the contract medical services portfolio at $90.2 million across 149 awards. This customer mix reflects Baylor's research-intensive mission and its integrated clinical delivery role supporting the VA system in transplant and specialized diagnostics.

Baylor sits on limited named parent vehicles in the source data—an Indefinite Delivery Contract (N0014098G2419) carrying 31 task orders valued at $519 thousand, a Vaccine and Treatment Evaluation Units vehicle (20 task orders, $27.5 million), and several VA IDIQ contracts—but the vast majority of Baylor's footprint comprises direct NIH grants (project grants, training grants, center grants) and VA delivery orders issued against existing indefinite-delivery relationships, rather than participation in government-wide acquisition vehicles or BPAs typical of commercial contractors.

Activity trajectory shows maturation and then decline in recent years within the source coverage window. Awards per year peaked at 477 in 2024, declined to 249 in 2025, and dropped to 4 by early 2027 (partial-year data), reflecting both the lag in award publication and the institution's research funding environment. Obligated dollars ($9.25 billion) exceed combined potential value (246% ratio), indicating that many awards have been exercised, incremented, or obligated beyond their initial ceiling—typical for long-term research programs and multi-year grants.

Service Contract Inventory data (FY2022–FY2025) reveal SCI-reportable invoiced revenue of $25.7 million as prime across 72 records, with FY2022 anchoring activity at $13.4 million across 67.7 FTEs and FY2024 showing $6.8 million across 66.4 FTEs. Government-paid median hourly rates on federal service contracts run $123.77/hr, with a 90th percentile of $640.28/hr, consistent with research and clinical labor pricing. Across SCI-reportable prime contracts, subcontractors account for an average 6% of total contractor hours, indicating that Baylor builds most of its delivery teams internally; five named subcontractors appear in the SCI dataset. Baylor's role is predominantly prime (81% of awards) rather than sub (19%), and in the SCI context, the institution serves as the lead service provider rather than a feeder to larger primes.

Subsidiaries named in the source include Baylor Miraca Genetics Laboratories LLC (for-profit limited liability company, genetics testing and diagnostics) and Xploration Health LLC (for-profit, health services), both extending Baylor's clinical and translational research capabilities into specialized laboratory and health services offerings. These entities expand the institutional portfolio into precision diagnostics and health innovation delivery alongside the core academic medical research mission. Teaming relationships visible in the grant sub-award footprint show Baylor acting as a sub-recipient or clinical site partner for multicenter consortia sponsored by peer research institutions—including partnerships with Columbia University (microphysiological systems research), Emory University (pediatric and oncology research), Children's Hospital Philadelphia (multi-site studies), and university systems across the country—reinforcing Baylor's role as a leading academic medical research engine within the NIH ecosystem.